Subscribe to our newsletter.
AML (Acute Myeloid Leukemia) encompasses a fast-growing form of blood cancer that originates in the bone marrow. It primarily affects white blood cells, disrupting their normal function and leading to a variety of health issues, such as infection susceptibility, fatigue, and bleeding disorders. AML is diagnosed through a combination of blood tests, bone marrow exams, and genetic testing. Understanding specific gene mutations linked to AML, such as FLT3, IDH1, or IDH2, is crucial for prognosis and treatment selection. Advances in targeted therapies have opened up new avenues for treating AML based on its genetic profile, allowing for more personalized and potentially effective treatment options.